Patents by Inventor Gilles Borrelly

Gilles Borrelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Publication number: 20130243855
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Application
    Filed: November 14, 2012
    Publication date: September 19, 2013
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Patent number: 8383388
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: February 26, 2013
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120264686
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: October 18, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified erythropoietin polypeptides and uses thereof for treatment
    Patent number: 8252743
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: August 28, 2012
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof
    Patent number: 8222209
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: July 17, 2012
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120094906
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: April 19, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • HMGB1 high affinity binding domain Box-A mutants
    Patent number: 8058232
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: November 15, 2011
    Assignee: Creabilis Therapeutics S.p.A.
    Inventors: Silvano Fumero, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Modified growth hormones
    Patent number: 7998930
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 16, 2011
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • Modified growth hormones
    Publication number: 20110130331
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Application
    Filed: January 25, 2011
    Publication date: June 2, 2011
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1
    Publication number: 20110052493
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Application
    Filed: November 9, 2009
    Publication date: March 3, 2011
    Applicant: CREABILIS THERAPEUTICS S.P.A.
    Inventors: Silvano FUMERO, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Modified growth hormone
    Patent number: 7884073
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: February 8, 2011
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)
    Patent number: 7635679
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: December 22, 2009
    Assignee: Creabilis Therapeutics S.p.A.
    Inventors: Silvano Fumero, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Modified erythropoietin polypeptides and uses thereof
    Publication number: 20090238789
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: November 28, 2007
    Publication date: September 24, 2009
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Oral dosage formulations of protease-resistant polypeptides
    Publication number: 20080260820
    Abstract: Oral dosage formulations of the protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, including enteric-coated forms. Methods for treatment or prevention of diseases or conditions that are treatable or preventable by the administration of such oral dosage formulations of protease-resistant polypeptides are provided.
    Type: Application
    Filed: April 19, 2007
    Publication date: October 23, 2008
    Inventors: Gilles Borrelly, Caroline Chauchard, Lila Drittanti, Manuel Vega
  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Publication number: 20080102115
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Application
    Filed: June 15, 2007
    Publication date: May 1, 2008
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human Box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
    Publication number: 20080038309
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Application
    Filed: March 5, 2007
    Publication date: February 14, 2008
    Applicant: CREABILIS THERAPEUTICS S.p.A.
    Inventors: Silvano Fumero, Luisa Bertarione Rava Rossa, Domenico Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Modified interferon-beta (IFN-beta) polypeptides
    Publication number: 20080038224
    Abstract: Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid molecules. The modified polypeptides exhibit increased protein stability, including increased resistance to proteases. Also provided are methods of treatment by administering modified interferon-beta polypeptides.
    Type: Application
    Filed: March 27, 2007
    Publication date: February 14, 2008
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • Modified growth hormones
    Publication number: 20080026993
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Application
    Filed: June 26, 2006
    Publication date: January 31, 2008
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • Modified interferon-beta (IFN-beta) polypeptides
    Publication number: 20080003202
    Abstract: Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid molecules. The modified polypeptides exhibit increased protein stability, including increased resistance to proteases. Also provided are methods of treatment by administering modified interferon-beta polypeptides.
    Type: Application
    Filed: March 27, 2007
    Publication date: January 3, 2008
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • Modified growth hormones
    Publication number: 20070249532
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Application
    Filed: November 3, 2005
    Publication date: October 25, 2007
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega